End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
790,000 KRW | +1.80% | -1.86% | +3.95% |
Apr. 08 | Samsung Biologics Boosts Contract Size with MSD Switzerland | MT |
Mar. 20 | Samsung Life Science Fund Invests in Biologics Developer | MT |
Sales 2024 * | 4,261B 3.09B | Sales 2025 * | 4,956B 3.6B | Capitalization | 56,227B 40.82B |
---|---|---|---|---|---|
Net income 2024 * | 973B 706M | Net income 2025 * | 1,182B 858M | EV / Sales 2024 * | 12.7 x |
Net cash position 2024 * | 1,928B 1.4B | Net cash position 2025 * | 2,792B 2.03B | EV / Sales 2025 * | 10.8 x |
P/E ratio 2024 * |
58.5
x | P/E ratio 2025 * |
48.9
x | Employees | 4,284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.25% |
1 day | +1.80% | ||
1 week | -1.86% | ||
Current month | -4.93% | ||
1 month | -4.36% | ||
3 months | +4.50% | ||
6 months | +9.57% | ||
Current year | +3.95% |
Managers | Title | Age | Since |
---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 17-12-31 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 2 M€ | -14.14% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 790,000 | +1.80% | 33,200 |
24-04-17 | 776,000 | -1.15% | 29,827 |
24-04-16 | 785,000 | -1.01% | 43,773 |
24-04-15 | 793,000 | +0.38% | 31,597 |
24-04-12 | 790,000 | -0.63% | 41,353 |
End-of-day quote Korea S.E., April 17, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.95% | 39.93B | |
-5.32% | 84.57B | |
-26.37% | 27.93B | |
+52.09% | 24.21B | |
-6.59% | 17.17B | |
-32.37% | 13.93B | |
-10.45% | 12.3B | |
-15.88% | 11.84B | |
-2.85% | 7.91B | |
+0.53% | 7.48B |
- Stock Market
- Equities
- A207940 Stock